Background: We assessed the laboratory diagnosis and treatment of invasive fungal disease (IFD) in Italy to detect limitations and potential for improvement. Methods: The survey was available online at www.clinicalsurveys.net/uc/IFI management capacity/, and collected variables such as (a) institution profile, (b) perceptions of IFD in the respective institution, (c) microscopy, (d) culture and fungal identification, (e) serology, (f) antigen detection, (g) molecular tests, (h) susceptibility testing and (i) therapeutic drug monitoring (TDM). Results: The laboratory capacity study received responses from 49 Italian centres, with an equitable geographical distribution of locations. The majority of respondents (n = 36, 73%) assessed the occurrence of IFD as moderate-high, with Aspergillus spp. being the pathogen of highest concern, followed by Candida spp. and Mucorales. Although 46 (94%) of the institutions had access to microscopy, less than half of them performed direct microscopy on clinical specimens always when IFD was suspected. Cultures were available in all assessed laboratories, while molecular testing and serology were available in 41 (83%), each. Antigen detection tests and antifungal drugs were also generally accessible (> 90%) among the participating institutions. Nevertheless, access to TDM was limited (n = 31, 63%), with a significant association established between therapeutic drug monitoring availability and higher gross domestic product per capita. Conclusions: Apart from TDM, Italy is adequately prepared for the diagnosis and treatment of IFD, with no significant disparities depending on gross domestic product. Future efforts may need to focus on enhancing the availability and application of direct microscopic methods, as well as TDM, to promote optimal treatment and better patient outcomes.
Monoclonal antibodies, such as bamlanivimab and etesevimab combination (BEC), have been proposed for patients with mild or moderate coronavirus disease 2019 (COVID-19). However, few studies have assessed the factors associated with the early administration of BEC or the impact of early BEC treatment on the clinical evolution of the patients. We conducted a retrospective cohort study of all adults with COVID-19 who received BEC at three institutions in the Liguria region. The primary endpoint was to investigate the clinical variables associated with early BEC infusion. Secondary endpoints were 30-day overall mortality and the composite endpoint of requirement of hospital admission or need for supplemental oxygen during the 30-day follow-up period. A total of 127 patients (median age 70 years; 56.7% males) received BEC. Of those, 93 (73.2%) received BEC within 5 days from symptoms onset (early BEC). Patients with a higher Charlson comorbidity index were more likely to receive early treatment (odds ratio (OR) 1.60, 95% confidence interval (CI) 1.04–2.45; p = 0.03) in contrast to those reporting fever at presentation (OR 0.26, 0.08–0.82; p = 0.02). Early BEC was associated with lower likelihood of hospital admission or need for supplemental oxygen (OR 0.19, 0.06–0.65; p = 0.008). Five patients who received early BEC died during the follow-up period, but only one of them due to COVID-19-related causes. Early bamlanivimab and etesevimab combination was more frequently administered to patients with a high Charlson comorbidity index. Despite this, early BEC was associated with a lower rate of hospital admission or need for any supplementary oxygen compared to late administration. These results suggest that efforts should focus on encouraging early BEC use in patients with mild–moderate COVID-19 at risk for complications.
Introduction The management of complicated Gram-positive bloodstream infections (cBSI) and infective endocarditis (IE) often requires prolonged intravenous therapy. Transition to oral therapy is frequently unfeasible because of resistance, drug interactions, or adherence concerns, increasing the risk of intravenous-related complications and healthcare burden. The pharmacokinetic profile and spectrum of oritavancin may enable effective treatment and early discharge. This study evaluated its effectiveness, safety, and impact on hospital resource use in patients with cBSI or IE. Methods We conducted a multicenter, retrospective, observational study across eight hospitals in Italy and Spain (April 2023–February 2025). Adult patients with Gram-positive cBSI (persistent/refractory BSI or prosthetic material) or IE (2023 modified Duke criteria) treated with ≥ 1 dose of oritavancin were included. Dosing was determined by the treating physicians. Data on outcomes, adverse events (AEs) and healthcare use were collected from medical records. Patients were followed for at least 6 months. Results Twenty-seven patients were included: 13 (48.1%) cBSI and 14 (51.9%) IE. Median age was 73 years (IQR 65–81); 18 out of 27 (66.7%) were male; Charlson Comorbidity Index 6 (IQR 4–7). In cBSI, oritavancin was first-line in 6/13 (46.2%) and given in multiple doses in 8/13 (61.6%), median of 2 doses (IQR 2–2.5). Clinical success was 100%, with no recurrence or BSI-related mortality. In IE, Staphylococcus aureus was identified in 5 of 14 cases (35.7%), of which 40% were methicillin-resistant. Native valves were involved in 6/14 (42.8%), prosthetic valves in 6/14 (42.8%), cardiac devices in 2/14 (14.3%). Clinical success was achieved in 85.7% of patients with IE (12/14). Two AEs occurred: nausea and a non-fatal acute coronary syndrome in a patient with pre-existing ischemic heart disease. Oritavancin use reduced 369 hospital days with potential savings of approximately €4235 per patient. Conclusions Oritavancin may represent a safe, effective treatment option for selected patients with cBSI or IE, with advantages in outcomes, reduced hospital stay, and cost containment.
Background: Current international guidelines lack clear recommendations on the management of non‐colonised patients undergoing intra‐hospital transfer from the ward in which horizontal transmission of Candida auris is known to occur (defined as endemic for Candida auris ) to wards with no horizontal transmission detected (defined as non‐endemic wards), particularly regarding the timing and number of screening swabs needed to exclude colonisation. Methods: Single‐center prospective observational study at a tertiary‐care hospital in Genoa, Italy, including adults transferred from the C. auris endemic‐ICU (eICU) to non‐endemic wards between January and December 2024. Patients who tested negative for C. auris colonisation both at eICU admission and at transfer, and who had ≥ 1 screening swab performed post‐transfer, were included. Swabs (bilateral axilla/groin) were performed on Days 0–1, 2–3 after transfer, and then weekly, and tested for C. auris with real‐time PCR. Patients were considered sufficiently screened to exclude colonisation if they underwent ≥ 2 swabs within the first 4 weeks after transfer. Results: Among 462 patients transferred from the eICU, 440 (95.2%) were non‐colonised. Among them, 275 (62.5%) met inclusion criteria, and 208 (75.6%) were considered sufficiently screened. C. auris colonisation was detected in 34/208 (16.3%) patients, with 21 (61.8%) positive in the first post‐transfer swab. Among 99 patients who had a negative result of a swab performed within 1 day before transfer, 7 (7.1%) resulted later positive. C. auris candidemia occurred in 4/34 (11.8%) patients with colonisation detected post‐transfer, compared to 1/35 (2.9%) patients found colonised during eICU stay, and none occurred in non‐colonised individuals. Conclusions: A single negative screening test at eICU discharge is insufficient to exclude colonisation, even if performed within 24 h from transfer. Repeated screening, ideally within the first 2 weeks post‐transfer, is essential to detect colonisation and prevent further C. auris transmission.
11 October 2025 in Journal of Global Antimicrobial Resistance
This study evaluated the impact of pre-existing resistance-associated mutations (RAMs) to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) on treatment outcomes in people living with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a real-world setting. We conducted a single-centre, retrospective review of treatment-experienced adult PWH switched to B/F/TAF, comparing those with and without NRTI RAMs. The primary endpoint was virological success at week 96 (<50 HIV RNA copies/mL). Secondary endpoints were changes in absolute CD4+ counts and CD4+/CD8+ ratio. Continuous variables were analysed using the Wilcoxon rank sum test and categorical variables with the Chi-square or Fisher's exact test. Longitudinal changes in absolute CD4+ counts and CD4+/CD8+ ratio were assessed using linear mixed-effects models, accounting for repeated measurements over time. A total of 257 PWH were included, of whom 21 were viraemic at the time of switch; 41 had pre-existing NRTI RAMs, while no RAMs were documented in the remaining 216 participants. At week 96, virological suppression was achieved in 100% of individuals with RAMs and 97.2% of those without NRTI RAMs, respectively (P = ns). Absolute CD4+ counts increased in 44.4% of participants, with no significant impact of NRTI RAMs. The CD4+/CD8+ ratio showed an apparent increase of more than 50% in 73.2% and 62.0% of participants with and without NRTI RAMs, respectively. However, longitudinal trend analysis revealed a significant negative rate of change in both groups, which was less pronounced among participants with RAMs. B/F/TAF is an effective treatment option for PWH with NRTI RAMs.
1 September 2026 in Expert Review of Anti-infective Therapy
1. Skin and soft tissue infections (SSTIs) represent one of the most frequent reasons for medical evaluation in both emergency departments (ED) and inpatient settings across different healthcare sy...
About Me
Medical student born in Milan and actually studying in Genoa, Italy.
Medical student born in Milan and actually studying in Genoa, Italy.